Study Details

Back
Study ID 5094-CL-0102
Study Title A Phase 1, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate (5094-CL-0102)
Clinicaltrials.gov Identifier NCT02698657
Compound Name ASP5094
Medical Indication or Disease Rheumatoid arthritis
Study Sponsor Astellas Pharma Global Development, Inc.
Collaborator Not Applicable
Study Start Date 23-Feb-2016
Study Completion Date 07-Sep-2017
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
English

QUICK SEARCH

USEFUL LINKS